AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05497830 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RISK-INDEX
Description: Presentation of RISKINDEX to the physician after approximately 2 hours. The ML RISKINDEX is a prediction model based on laboratory data from the ED. It is based on date of birth, sex and at least four laboratory data which are sampled within the first two hours of the ED visit. Laboratory data that are used as input include samples that are commonly drawn in patients that require treatment from an internal medicine physician, such as urea, albumin, C-reactive protein (CRP), lactate and bilirubin.
Study NCT05990179 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genome sequencing-based newborn screening
Description: Dried blood spots collected at birth for routine newborn screening will be used for genome sequencing based screening of a defined set of conditions.
Study NCT05592665 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Survey Questionnaire
Description: Study participants will complete several questionnaires/assessments via PRO-Core standardized email communication or via telephone with a study team member.
Study NCT05198921 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive Transcranial Magnetic Stimulation
Description: To apply the rTMS will be used the device Neuro-MS/D Variant-3 therapeutic advanced (Neurosoft, Russia) with double cone shape coil. The coil will be placed at Cz according to 10-20 system.~The rTMS protocol will be:~Train frequency - 10 Hz Train duration - 10 sec Inter train interval - 50 seconds Number of train - 25~------------------------------------- Total pulses - 2500 Total session duration - 1500 seconds
Study NCT05198921 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: repetitive Transcranial Magnetic Stimulation
Description: To apply the rTMS will be used the device Neuro-MS/D Variant-3 therapeutic advanced (Neurosoft, Russia) with double cone shape coil. The coil will be placed at Cz according to 10-20 system.~The rTMS protocol will be:~Train frequency - 10 Hz Train duration - 10 sec Inter train interval - 50 seconds Number of train - 25~------------------------------------- Total pulses - 2500 Total session duration - 1500 seconds
Study NCT05198921 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham repetitive Transcranial Magnetic Stimulation
Description: Neuro-MS/D magnetic stimulator (Neurosoft, Russia) with Neuro-MS.NET software will be used. The synchronous sound will be performed using monitor speaker connected to magnetic stimulator via trigger unit and located near discharging coil. The 10-Hz electrical stimulation will be given trough electrodes fixed on the head along the front edge of the coil to mimic the sensation
Study NCT05198921 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham repetitive Transcranial Magnetic Stimulation
Description: Neuro-MS/D magnetic stimulator (Neurosoft, Russia) with Neuro-MS.NET software will be used. The synchronous sound will be performed using monitor speaker connected to magnetic stimulator via trigger unit and located near discharging coil. The 10-Hz electrical stimulation will be given trough electrodes fixed on the head along the front edge of the coil to mimic the sensation
Study NCT05670093 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neural Pressure Support (mode of mechanical ventilation)
Description: Nasogastric tube will be removed and replaced by a Esophageal catheter and Electrical Diaphragm activity catheter and mechanical ventilation in mode Neural Pressure Support
Study NCT05954130 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Sexual Health in Pregnancy
Study NCT05545930 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hand Wrung
Description: Hand wrung refers to manually wringing surgical sponges by hand.
Study NCT05545930 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ProCell Wrung
Description: ProCell wrung refers to automated wringing surgical sponges by an FDA approved suction device (ProCell).
Study NCT04718415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sintilimab, paclitaxel, carboplatin
Description: Patients receive sintilimab IV on day 1, paclitaxel IV on day 1 and carboplatin IV on day 1 . Treatment repeats every 21 days for up to 2 - 4 courses in the absence of disease progression or unacceptable toxicity.
Study NCT04718415 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical resection
Description: Surgical therapy will be at the discretion of the treating surgeon per standard of care.
Study NCT06147986 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic umbilical cord mesenchymal stem cells
Description: UMSC01 cells will be IC infusion followed by IV infusion with 24 months of follow up after treatment.
Study NCT06147986 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: Standard-of-care for STEMI
Study NCT06177483 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 95% curcumin extract powder
Description: 95% curcumin extract powder
Study NCT06177483 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: curQ+ curcumin formulation
Description: curQ+ curcumin formulation
Study NCT06357247 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sensory Threshold
Description: Using a light, vibrotactile noise device on the participant's affected wrist. The actuator will be positioned on both the dorsal and volar sides of the wrist. Each participant's sensory threshold will be measured using the method of ascending and descending limits
Study NCT06357247 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nine Hole Peg Test
Description: The Nine-Hole Peg Test (NHPT) is considered as a gold standard measure of manual dexterity and most frequently used in MS research and clinical practice. The score for the 9-HPT is an average of the four trials. The two trials for each hand are averaged, converted to the reciprocals of the mean times for each hand and then the two reciprocals are averaged. On average, healthy male adults complete the NHPT in 19.0 seconds (SD 3.2) with the right hand, and in 20.6 seconds (SD 3.9) with the left hand.
Study NCT06357247 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Semmes Weinstein Monofilament Assessment
Description: A non-invasive, low-cost, simple, and accurate handheld calibrated nylon thread that buckles once it has delivered a force of 10 g. It provides a standardized measure of a patient's ability to sense a point of pressure. The filaments are classified from grade 1 to 5 according to their thickness: 1.65-2.83 = grade 5, 3.22-3.61 = grade 4, 3.84-4.31 = grade 3, 4.56-6.45 = grade 2, and 6.65 = grade 1.
Study NCT04844827 — intervention group
Intervention type: GENETIC
Intervention: Conserving routinely performed pleural biopsies in our biological resources center to realize multiomics and bioinformatics analyzes secondarily
Description: Interventions will consist of a diagnostic and symptomatic videothoracoscopy in patients with pleural metastasis under general anesthesia, as part of a standard of care procedure. Fragments of these pleural biopsies (one for routine diagnosis and two for scientific purposes) will enrich the biocollection. Five blood samples will be taken at the time of surgery (3 to 5 ml / tube). These biological samples will be stored in the HCL CRB tumor bank. At the same time, patient demographic data will be collected and anonymized. In the long term, the biological material will be used by IARC for carrying out multi-omics and bioinformatics analyzes
Study NCT05220618 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Autobiographical Memory Specificity and Savoring Training: PESCAR
Description: An autobiographical memory specificity and savoring training has been developed by authors, based on previous training within the frame of Cognitive Bias Modification Interventions (CBM-I; Barry et al., 2019; Hitchcock et al., 2017) and savoring interventions (Bryant et al., 2005; Hanson et al., 2023). The training group will receive a self-guided intervention, which consists of an initial session (lasting 20 minutes approximately) and two-week training, conducted online. Participants will be provided with an online platform for following the intervention in a self-guided modality. The first session aims to give information about autobiographical memory functioning, to train in specificity recall through concrete processing steps and to explain the functioning of the self-guided modality. Then, during the next two weeks, participants will use the online platform once a day for practising the recall of autobiographical memories during 10-15 min approximately.
Study NCT06491446 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABI-2280
Description: Different strength of ABI 2280 will be administered in different cohorts.~Other: Placebo Matching placebo will be administered.
Study NCT04327700 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TheraBionic
Description: Amplitude-modulated electromagnetic fields will be self-administered and given continuously to patients in three courses of 60-minute treatments per day, administered in the morning, at noon and in the evening at the patient's home, with the exception of the first 60-minute treatment, which will be delivered at the research site. Each 4 week treatment period will be considered a cycle of treatment.
Study NCT04327700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Patients will receive 160 mg regorafenib (four 40 mg tablets) orally once daily for the first 3 weeks of each 4-week cycle per approved prescribing information.
Study NCT05010707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transdermal patch
Description: Participants will be prescribed the medication and dosed based on their hormonal profile. Goal is achieve estradiol level between 100-200 pg/mL and to suppress testosterone to cisgender female levels
Study NCT05010707 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Pro-thrombotic markers
Description: Once participants are started on gender affirming hormone therapy, pro-thombotic markers will be checked at baseline and every 6 months. Pro-thrombotic markers will include: Factor II, Factor IX, Factor XI, Von Willebrand factor, Protein C, Protein S, activated Protein C resistance.
Study NCT05010707 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Metabolic markers
Description: Once participants are started on gender affirming hormone therapy, metabolic markers will be checked at baseline and every 6 months. Markers will include: Insulin level, fasting glucose, body mass index, waist circumference.
Study NCT05010707 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Hormone Profile
Description: Once participants are started on gender affirming hormone therapy, hormonal levels will be checked every 4 weeks until estradiol and testosterone levels are within goal as established by standard of care.
Study NCT05010707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daily Sublingual Tablet
Description: Participants will be prescribed the medication and dosed based on their hormonal profile. Participants will take dose as once daily medication. Goal is achieve estradiol level between 100-200 pg/mL and to suppress testosterone to cisgender female levels
Study NCT05010707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BID Sublingual Tablet
Description: Participants will be prescribed the medication and dosed based on their hormonal profile. Participants will take dose as twice daily medication. Goal is achieve estradiol level between 100-200 pg/mL and to suppress testosterone to cisgender female levels
Study NCT05010707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone
Description: All patients will also receive spironolactone. Spironolactone will be started at 50 mg daily and will increase to standard dose.
Study NCT06066788 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: CHAMPS
Description: Cognitive Orientation to daily Occupational Performance is a performance-based treatment approach for children and adults who experience difficulties performing the skills they want to, need to or are expected to perform. Cognitive Orientation to daily Occupational Performance is a specifically tailored, active client-centered approach that engages the individual at the meta-cognitive level to solve performance problems. Focused on enabling success, the Cognitive Orientation to daily Occupational Performance Approach employs collaborative goal setting, dynamic performance analysis, cognitive strategy use, guided discovery, and enabling principles. These elements, all considered essential to the Cognitive Orientation to daily Occupational Performance Approach, are situated within a structured intervention format, and with parent/significant other involvement as appropriate.
Study NCT05391503 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Light therapy
Description: Morning bright light for 60 minutes after awakening
Study NCT05391503 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo light therapy
Description: Placebo morning bright light for 60 minutes after awakening
Study NCT06269133 — intervention group
Intervention type: DRUG
Intervention: REGN2810
Description: No study specific interventions for this non-interventional-observational study; patients had previously been administered this treatment.
Study NCT06269133 — intervention group
Intervention type: OTHER
Intervention: Platinum-doublet chemotherapy
Description: No study specific interventions for this non-interventional-observational study; patients had previously been administered this treatment.
Study NCT05380427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CU-40101
Description: CU-40101，0.0025% CU-40101，0.005% CU-40101，0.01% CU-40101，0.02%
Study NCT05380427 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CU-40101
Description: CU-40101，0.0025% CU-40101，0.005% CU-40101，0.01% CU-40101，0.02%
Study NCT06397677 — intervention group
Intervention type: GENETIC
Intervention: Research Testing Performed (Laboratory)
Description: Blood collection (DNA, RNA)
Study NCT06650709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib 300mg orally twice daily on a continuous dosing schedule for a maximum of 3 x 28-day cycles.
Study NCT06650709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 10mg/kg intravenously on Day 1 and 15 of the 28 day cycle for a maximum of 3 cycles (Cycle 3, Day 15 will be omitted).
Study NCT06650709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1500mg intravenously on Day 1 of the 28 day cycle for a maximum of 3 cycles.
Study NCT06655376 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: 81-100 mg, oral
Study NCT06655376 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Warfarin dose will be adjusted per patient for a goal INR 2-3. The individualized daily dose could range anywhere from 0.5-2 mg to 5-7 mg. Oral.
Study NCT06655376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Warfarin dose will be adjusted per patient for a goal INR 2-3. The individualized daily dose could range anywhere from 0.5-2 mg to 5-7 mg. Oral.
Study NCT06603116 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: treatment of class two cavities
Description: restorations in class 2 cavities
Study NCT06603116 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: treatment of class two cavities
Description: restorations in class 2 cavities
Study NCT06604273 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fibroblast Activation Protein Inhibitor
Description: PET CT imaging using the fibroblast activation protein inhibitor tracer
Study NCT06603974 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: After receiving the corresponding neoadjuvant treatment for 2 cycles, surgery was performed within 3-6 weeks after drug withdrawal.
Study NCT06603974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benmelstobart
Description: 1200mg, diluted to 250ml with normal saline, infusion time 60 ± 10mins. The first day of each cycle, 3 weeks (21 days) as a treatment cycle
Study NCT06603974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tegafur
Description: it needs to be administered according to the patient\&#39;s body surface area\&lt; 40mg / time at 1.25m2; \&gt; 50mg/ time for 1.25m2 and \&lt;1.5m2; \&gt; 60mg/ time at 1.5m2; Oral, twice a day, after morning and evening meals, for 14 consecutive days, rest for 7 days, as a treatment cycle; Repeat every 3 weeks;
Study NCT06603974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: 130mg/m2, administered on the first day of each cycle, repeated every 3 weeks;
Study NCT06603974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albumin paclitaxel
Description: 260mg/m2, intravenous infusion, 30 minutes per infusion, once every 3 weeks, administered on the first and eighth days of each cycle
Study NCT06586996 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT06595160 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study
Study NCT06592417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JSKN016 injection
Description: JSKN016 is a bispecific antibody drug conjugate targeting HER3 and TROP2.
Study NCT05762757 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Colposcopy educational material
Description: -Will consist of a handout featuring education and information regarding colposcopies.
Study NCT06589921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone Modified-Release Tablets
Description: take the tablet under fed condition, 1 tablet at a time, once a day.
Study NCT06589921 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pirfenidone Tablets
Description: ake the tablet under fed condition, 1 tablet at a time, three times a day.
Study NCT06592677 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Condensed internet-delivered prolonged exposure (CIPE)
Description: 'Condensed Internet-delivered Prolonged Exposure' (CIPE) is an intervention designed for victims with symptoms of post-traumatic stress disorder (PTSD) soon after a traumatic incident. CIPE is a therapist-supported intervention that consists of four modules delivered over the internet. Central CIPE-interventions include psychoeducation of normal post-traumatic reactions, in-vivo exposure, imaginary exposure, and a breathing exercise.
Study NCT06592677 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment-as-usual (TAU)
Description: There is currently considerable heterogeneity regarding the interventional principles applied in the Treatment-as-usual (TAU) condition across municipal crisis teams. The national guidelines (The Norwegian Directorate of Health, 2016), recommends several interventional principles such as psychological first aid (PFA), psychoeducation regarding crisis reactions/symptoms of acute stress, normalization of such reactions, activation of social support, and practical assistance.
Study NCT06592677 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment-as-usual (TAU)
Description: There is currently considerable heterogeneity regarding the interventional principles applied in the Treatment-as-usual (TAU) condition across municipal crisis teams. The national guidelines (The Norwegian Directorate of Health, 2016), recommends several interventional principles such as psychological first aid (PFA), psychoeducation regarding crisis reactions/symptoms of acute stress, normalization of such reactions, activation of social support, and practical assistance.
Study NCT06397677 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Information Collected as Standard of Care
Description: High Resolution CT Scan (Chest), Pulmonary Function Testing (PFT), 6-Minute Walk Test (6MWT)
Study NCT06397677 — intervention group
Intervention type: OTHER
Intervention: Research Testing Performed
Description: Blood collection (non-genetic), Buccal Swab, Rheumatologic Assessment, Pulmonary Assessment, Questionnaires
Study NCT06307028 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SISTA-P Intervention
Description: This intervention is a small group discussion designed specifically for Black women. The sessions cover topics including: self pride and self-care; HIV \& PrEP education; assertiveness skills training; coping skills; skills practice; and barriers and facilitators to HIV prevention and PrEP.
Study NCT06217809 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The intervention curriculum addresses sexual activity, abstinence, and adulthood preparation topics.
Description: The intervention is gender-specific, youth-co-led, and targets minorities through a 16-unit curriculum totaling 20 hours. Each participant and their parent/guardian will also receive one individual session with a case planner. Parents will receive 3 hours of parental support group. EmpowHer contains lessons and activities focusing on topics relating to sexual health and teen pregnancy prevention, focusing on adulthood preparation subjects (APS), such as parent-child communication, adolescent development, healthy life skills, and healthy relationships.
Study NCT06068595 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: musculoskeletal ultrasound
Description: After clinical examination and medical interrogation, The investigating physician gives her decisions in the e-CRF according to the 5 axes: diagnosis (I), therapy (II), patient referral (III), prescription of additional tests (IV) and follow-up (V). The investigator performs the targeted musculoskeletal ultrasound with his personal ultrasound machine, following his usual operating procedure and give/keep the final diagnostic.